Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2021 Jul 16;23(9):105.
doi: 10.1007/s11912-021-01091-1.

Approaches to Non-Muscle-Invasive Bladder Cancer

Hannah Slovacek  1 , Jerry Zhuo  2 , Jennifer M Taylor  3
Affiliations
Review

Approaches to Non-Muscle-Invasive Bladder Cancer

Hannah Slovacek et al. Curr Oncol Rep. .

Abstract

Purpose of review: Non-muscle-invasive bladder cancer (NMIBC) is a heterogenous malignancy with high recurrence and progression rates, which necessitate uniform recommendations for diagnosis and management. Herein, we review the literature, with an emphasis on guidelines and contemporary diagnostic techniques and interventions.

Recent findings: Guidelines around the world have adopted a schema which risk-stratify cases at diagnosis, to offer evidence-based treatment and surveillance recommendations. Enhanced endoscopic technologies can improve detection of NMIBC and reduce recurrence. The present Bacillus Calmette-Guerin (BCG) shortage in the USA has led to new strategies to prioritize the most high-risk cases. The entity of BCG-unresponsive high-risk NMIBC remains a challenge to manage, with multiple novel treatments under investigation; fortunately, new therapies have been approved, such as immune checkpoint inhibitors, and others are showing tremendous promise. The standardization of NMIBC management, with evolving detection techniques and therapeutics, offers great potential to improve patient outcomes and survivorship.

Keywords: BCG; Bladder cancer; Intravesical therapy; Non-muscle-invasive bladder cancer; Survivorship.

PubMed Disclaimer

References

Papers of particular interest, published recently, have been highlighted as: • Of importance •• Of major importance
    1. Calderone C, Taylor JM. Urothelial cancer of the bladder: treatment of early stage disease. Handb Prostate Cancer Genitourin Malig. 2017. p. 157.
    1. Cumberbatch MGK, Jubber I, Black PC, Esperto F, Figueroa JD, Kamat AM, et al. Epidemiology of bladder cancer: a systematic review and contemporary update of risk factors in 2018. Eur Urol. 2018;74:784–95. - PubMed - DOI
    1. Babjuk M, Burger M, Compérat EM, Gontero P, Mostafid AH, Palou J, et al. European Association of Urology Guidelines on non-muscle-invasive bladder cancer (TaT1 and carcinoma in situ) - 2019 update. Eur Urol. 2019;76:639–57 This paper describes the current and updated European Association of Urology guidelines for diagnosis and management of non-muscle-invasive bladder cancer. - PubMed - PMC - DOI
    1. Howlander N, Noone A, Krapcho M, Breast A, Yu M, Ruhl J, et al. SEER cancer statistics review, 1975-2017 [Internet]. Cronin K, editor. National Cancer Institute, Bethesda, MD; Available from: https://seer.cancer.gov/csr/1975_2017/
    1. Chang SS, Boorjian SA, Chou R, Clark PE, Daneshmand S, Konety BR, et al. Diagnosis and treatment of non-muscle invasive bladder cancer: AUA/SUO guideline. J Urol. 2016;196:1021–9 Amended in 2020, this article reports the current American Urological Association guidelines for diagnosis and treatment of non-muscle-invasive bladder cancer. - PubMed - DOI

Publication types

LinkOut - more resources